Compare LVO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LVO | MAIA |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.9M | 79.0M |
| IPO Year | 2010 | 2022 |
| Metric | LVO | MAIA |
|---|---|---|
| Price | $4.49 | $1.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | 42.7K | ★ 584.3K |
| Earning Date | 06-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.57 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $77,144,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.87 |
| 52 Week High | $7.19 | $3.19 |
| Indicator | LVO | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
LiveOne Inc creator-first, music, entertainment and technology platform focused on delivering premium experiences and content world'wide through paid users and live and virtual events. It is in the acquisition, distribution and monetization of live music events, Internet radio, podcasting/vodcasting and music-related membership, streaming and video content. It provide services through a dedicated over-the-top application powered by Slacker (LiveOne App) called LiveOne. The company has three operating segments, PodcastOne, Slacker and Media Group. The company generates majority of revenue from PodcastOne. The Company's operations are based in the United States.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.